Therapeutics News and Research

RSS

Stong evidence for lower penicillin allergic reactions

Researchers at the University of Pennsylvania School of Medicine have concluded the world's largest analysis of penicillin allergy due to re-prescription of the popular antibiotic.

14 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004

New MRI Liver Contrast Agent Primovist(TM) Approved in Sweden

Schering AG Group, Germany has announced that the Swedish health authority MPA has granted marketing approval for its innovative liver imaging product Primovist(TM) (gadoxetic acid disodium). Primovist(TM) is designed for the detection and characterization of liver lesions by magnetic resonance imaging (MRI) including liver tumors, metastases as well as other malignant and benign lesions.

5 Apr 2004

Oxford Biomedica to win Department of Health gene funding

Oxford spinout Oxford Biomedica was yesterday awarded £0.5 million by the Department of Health to conduct the first British gene therapy haemophilia trial.

31 Mar 2004

How rat's genetic blueprint stacks up against those of mice and humans

An international research team, supported by the National Institutes of Health (NIH), today announced it has completed a high-quality, draft sequence of the genome of the laboratory rat, and has used that data to explore how the rat's genetic blueprint stacks up against those of mice and humans.

31 Mar 2004

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004

World’s largest biotechnology company acquires Tularik

Amgen Inc., the world’s largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene expression, today jointly announced that they have signed a definitive merger agreement whereby Tularik will become a wholly-owned subsidiary of Amgen in a stock for stock transaction.

30 Mar 2004

Cancer research boosted in Queensland Australia

The University of Queensland's Institute for Molecular Bioscience (IMB) is one of just three recipients of the largest research grant ever given by the Australian Cancer Research Foundation (ACRF).

29 Mar 2004

Air pollution effects Cystic Fibrosis Sufferers

University of Washington (UW) researchers have shown for the first time that air pollution has adverse effects on people with cystic fibrosis (CF). The research results are published in the April 1 edition of the American Journal of Respiratory and Critical Care Medicine.

29 Mar 2004

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

New vaccinations to prevent infections that lead to cervical cancer and targeted therapeutics aimed at breast cancer were examples of research highlights presented by scientists today at the 95th Annual Meeting of the American Association for Cancer Research. Scientists described advances that feed into the drug development 'pipeline,' and show strong promise for controlling existing tumors or addressing the pathogen that causes tumors.

29 Mar 2004

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

26 Mar 2004

New Computer-Aided Approach Helps Doctors Tailor The Dosage of Abciximab

A computer-aided approach -- based on software-that-learns, promises to provide a new tool that helps doctors tailor the dosage of abciximab, a medicine frequently used before angioplasty to lessen the chance of heart attack.

22 Mar 2004